Borgeson Blake's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed May 30, 2024
- Accession no.
- 0001601830-24-000067
- Filed
- May 30, 2024
- Trade date
- May 28, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $105.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Borgeson BlakeCIK 0001856094 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 28, 2024 | Class A Common Stock | SSaleDisposed | −11,447 | $9.17F2 | −$104,968.99 | 7,186,913 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $8.88 to $9.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.